- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Pharmacotherapeutic group: antimicrobial agent nitrofuran.
ATH code: A07AH03.
Nifuroxazide - intestinal antiseptic, a derivative of 5-nitrofuran, highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp; Clostridium perfingens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp. Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp, Pseudomonas spp.
Nifuroxazide presumably inhibits the activity of dehydrogenases and the synthesis of proteins in bacteria cells. Does not cause the emergence of drug-resistant strains, was not observed as cross-resistance with other antibacterial drugs. The effectiveness of nifuroxazide does not depend on the pH that exists in the intestinal lumen, nor on the sensitivity of microorganisms to antibacterial drugs. Does not affect the composition of the normal bacterial flora of the digestive tract. In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses prevents the development of bacterial superinfection.
After oral administration, nifuroxazide is practically not absorbed from the digestive tract and exerts its antibacterial action exclusively in the intestinal lumen. Nifuroxazide is eliminated by the intestines: 20% unchanged, and the rest is nifuroxazide - chemically modified.
Acute bacterial diarrhea, occurring without deterioration of the general condition, fever, intoxication.
1 capsule contains:
active ingredient: nifuroxazide 100/200 mg;
excipients: sugar (sucrose), extra category, corn starch, microcrystalline cellulose, magnesium stearate;
hard gelatin capsule: body and cap of the capsule - titanium dioxide, yellow iron oxide, gelatin.
Nifuroxazide is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Enterofuril||Bosnalek||Bosnia and Herzegovina||capsules|
|Enterofuril||Bosnalek||Bosnia and Herzegovina||suspension|
No customer reviews for the moment.
Dosage and Administration
It is applied inside. The capsule should be swallowed whole, washed down with a small amount of water.
Children from 3 to 6 years: 2 capsules 100 mg each or 1 capsule 200 mg 3 times a day (the interval between taking 8 hours).
Children from 6 to 18 years: 2 capsules of 100 mg or 1 capsule of 200 mg 3-4 times a day (the interval between doses of 6-8 hours).
Adults: 2 capsules, 100 mg each, or 1 capsule, 200 mg 4 times a day (the interval between doses is 6 hours).
Duration of treatment is 5-7 days, but not more than 7 days. If during the first 3 days of admission improvement has not come, then you should consult a doctor.
Use the drug only according to the method of use and in those doses that are specified in the instructions. If necessary, please consult a physician before using the drug.
Allergic reactions (skin rash, urticaria, angioedema, anaphylactic shock). If any of the side effects indicated in the instruction are aggravated, or you have noticed any other side effects that are not indicated in the instruction, inform your doctor.
Hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug, sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, pregnancy, children under 3 years of age.
The simultaneous use with drugs that cause the development of disulfiram-like reactions, drugs that depress the function of the central nervous system is not recommended. If you are taking other medications (including non-prescription), consult your doctor before use.
Pregnancy and Lactation
In animal studies, no teratogenic effect was detected. However, as a precautionary measure, taking nifuroxazide during pregnancy is not recommended.
During the breastfeeding period, breastfeeding may continue in the case of a short course of drug treatment. Need to consult a doctor.
In the treatment of diarrhea, rehydration therapy should be carried out simultaneously with nifuroxazide therapy.
In the case of bacterial diarrhea with signs of systemic lesions (worsening of the general condition, fever, symptoms of intoxication or infection), you should consult a doctor to decide on the appointment of systemic antimicrobial drugs.
During drug therapy, alcohol is prohibited.
If you experience symptoms of an allergic reaction (including shortness of breath, rash, itching), you should stop taking the drug.
It should be noted that 1 capsule with a dosage of 100 mg contains 0.036 g of sugar (sucrose), which is 0.0036 XE; 1 capsule dosage of 200 mg contains 0.071 g of sugar, which is 0.0071 XE.
Influence on ability to steer vehicles, mechanisms
The drug does not affect the ability to drive vehicles and mechanisms.
Symptoms of overdose are not known. Symptomatic treatment.
- Brand name: Nifural
- Active ingredient: Nifuroxazide
- Dosage form: Hard gelatin capsules No. 2 (for a dosage of 100 mg) or No. 0 (for a dosage of 200 mg) with the case and a lid of yellow color. The contents of the capsules are a mixture of powder and yellow granules.
- Manufacturer: Obolensky OP
- Country of Origin: Russia
- Determination of Nifuroxazide by Flow Injection Linear Adsorptive Stripping Voltammetry on a Screen-Printed Carbon Nanofiber Modified Electrode
- Synthesis of 5-nitrofuran-2 [14C] aldehyde diacetate and the antibacterial agent [14C]-nifuroxazide
- Double-blind study of traveller's diarrhoea using Nifuroxazide
- A new class of nifuroxazide analogues: Synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus
- Simultaneous determination of Nifuroxazide and Drotaverine hydrochloride in pharmaceutical preparations by bivariate and multivariate spectral analysis
- Determination of nifuroxazide in biological fluid by automated high-performance liquid chromatography with large-volume injection
- Catalysis of nifuroxazide formation by crosslinked poly(vinylpyridine)-supported acids
- Determination of nifuroxazide with polarography and adsorptive stripping voltammetry at mercury and carbon paste electrodes
- Voltammetric study of nifuroxazide at unmodified and Sephadex-modified carbon paste electrodes
- Nifuroxazide Photodecomposition: Identification of the (Z)-isomer by1H-NMR Study
- Hydrolytic and Reductive Transformations of Nifuroxazide
- Solvent effects on the stability of nifuroxazide complexes with cobalt(II), nickel(II) and copper(II) in alcohols
- Acute generalized exanthematous pustulosis induced by nifuroxazide
- Occupational contact allergy to nifuroxazide simulating prurigo nodularis
- Redox behaviour of nifuroxazide: generation of the one-electron reduction product
- Antioxidant activity and inhibition of aflatoxin B1-, nifuroxazide-, and sodium azide-induced mutagenicity by extracts from Rhamnus alaternus L.
- Caco-2 cells cytotoxicity of nifuroxazide derivatives with potential activity against Methicillin-resistant Staphylococcus aureus (MRSA)
- Genotoxicity of 2-nitro-7-methoxy-naphtho[2,1-b]furan (R7000): A case study with some considerations on nitrofurantoin and nifuroxazide
- OL-014 Nifuroxazide in the treatment of patients with giardiasis in the Russia
- A validated spectrofluorimetric method for the determination of nifuroxazide through coumarin formation using experimental design
- Effet du nifuroxazide sur Giardia intestinalis
- Etude de l'activite antibacterienne du nifuroxazide in vitro